Fate Therapeutics, Inc. (FATE)
1.15
-0.04
(-3.36%)
USD |
NASDAQ |
Apr 07, 16:00
1.19
+0.04
(+3.48%)
After-Hours: 20:00
Fate Therapeutics EPS Diluted (Quarterly) : -0.2715 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| MannKind Corp. | -0.0519 |
| Vertex Pharmaceuticals, Inc. | 4.651 |
| Ardelyx, Inc. | -0.0017 |
| ACADIA Pharmaceuticals, Inc. | 1.596 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.37M |
| Revenue (Quarterly) | 1.369M |
| Total Expenses (Quarterly) | 33.74M |
| Enterprise Value | 7.898M |
| Gross Profit Margin (Quarterly) | -123.7% |
| Profit Margin (Quarterly) | -2.36K% |
| Earnings Yield | -102.4% |
| Normalized Earnings Yield | -102.51 |